Infection with Respiratory Syncytial Virus (RSV) can result in serious illness and hospitalization for infants and older adults, creating a high health and financial burden in Canada.
We developed a dynamic transmission model for RSV that is specific to Canadian data, along with an economic component to model disease outcomes alongside disease and intervention costs. The ultimate goal was to provide the National Advisory Committee on Immunizations (NACI) with a model to test the cost-effectiveness of future RSV vaccines licensed in Canada.